BAVARIAN NORDIC Aktie

 

Lange war es recht ruhig um den Impfstoffspezialisten Bavarian Nordic. In dieser Woche konnte das Unternehmen jedoch für positive News sorgen. Zuvor griff das vom AKTIONÄR platzierte Abstauberlimit für die Aktie. DER AKTIONÄR erklärt die Details zu den jüngsten Entwicklungen und worauf es jetzt beim Impfstoff-Wert ankommt....

COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued over DKK 700 million to supply its MVA-BN® smallpox/mpox vaccine to an undisclosed country in 2026 and 2027....

COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from June 2, 2026 to July 10, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, June 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the third and final tranche of the planned buy-back program, under which the Company intends to repurchase own shares for up to DKK 500 million during 2026....

COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523....

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

COPENHAGEN, Denmark, May 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2026....

COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine....

COPENHAGEN, Denmark, May 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on March 12, 2026, has now been completed, reaching an aggregate amount of approximately DKK 200 million as planned. This represented the second tranche of a total planned share buy-back of up to DKK 500 million in 2026. Combined with the first tranche, shares of a total aggregate amount of approximately DKK 350 million have now been repurchased. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure....

COPENHAGEN, Denmark, May 4, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, April 27, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:...

COPENHAGEN, Denmark, April 20, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, April 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active immunization for the prevention of disease caused by chikungunya virus in individuals aged 12 years and above....

COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, April 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, March 30, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...

COPENHAGEN, Denmark, March 23, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....

COPENHAGEN, Denmark, March 16, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares for an amount up to DKK 200 million in the period from March 12, 2026 to May 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation....